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Summary 
Stem cell factor (SCF), also known as mast cell growth factor, kit ligand, and Steel factor, is the 
ligand for the tyrosine kinase receptor (SCFtL) that is encoded by the c-kit proto-oncogene. 
We analyzed the effects of recombinant human SCF (r-hSCF, 5-50 btg/kg/day, injected sub- 
cutaneously) on mast cells  and melanocytes in a phase  I  study of 10 patients with advanced 
breast carcinoma. A wheal and flare reaction developed at each r-hSCF injection site; by elec- 
tron microscopy, most dermal mast cells at these sites exhibited extensive, anaphylactic-type 
degranulation. A 14-d course ofr-hSCF significantly increased dermal mast cell density at sites 
distant to those injected with the cytokine and also increased both urinary levels of the major 
histamine metabolite, methyl-histamine, and serum levels of mast cell 0r  Five subjects 
developed areas of persistent hyperpigmentation at r-hSCF injection sites; by light microscopy, 
these sites exhibited markedly increased epidermal melanization and increased numbers of me- 
lanocytes. The demonstration that r-hSCF can promote both the hyperplasia and the functional 
activation of human mast cells and melanocytes in vivo has implications for our understanding 
of  the role of endogenous SCF in health and disease. These findings also indicate that the inter- 
action between SCF and its receptor represents a potential therapeutic target for regulating the 
numbers and functional activity of both mast cells and cutaneous melanocytes. 
T 
he  stem  cell factor receptor (SCFtL)  is  expressed on 
immature  hematopoietic progenitor cells,  mast  cells, 
melanocytes, and germ cells, and both in vitro studies and 
analyses of experimental animals indicate that stem cell fac- 
tor  (SCF)  is  critical for the survival and normal develop- 
ment  of these  cell types  (1-3).  Apart  from its  effects on 
mast  cells,  the  major actions  of SCF  in  hematopoiesis in 
vitro are to promote the survival of immature hematopoi- 
etic progenitor cells and to synergize with other hemato- 
poietic growth factors in promoting the proliferation and 
differentiation of committed progenitor cells (1-3). Accord- 
ingly,  Escherichia  coli-derived  recombinant  methionyl hu- 
man SCF (r-hSCF), which represents essentially  the entire 
extracellular ligand  domain  of the  native  transmembrane 
molecule, as well as the most prevalent native soluble mol- 
ecule, has been introduced into phase I clinical trials; pre- 
liminary results indicate that r-hSCF may indeed be useful 
in mobilizing hematopoietic progenitors into the  circula- 
tion and in promoting hematopoiesis (4). 
However,  SCF  has  an  exceedingly  complex  biology; 
r-hSCF  certainly  represents  the  most  pleiotropic  of the 
"hematopoietic" growth factors that have been introduced 
into the  clinic.  For example, recombinant SCF  can pro- 
mote mast cell hyperplasia in mice (5), rats (5), and nonhu- 
man primates (6) in vivo; human mast cell development in 
vitro  (7-10);  degranulation  and  mediator  release  from 
mouse dermal mast cells in vivo (11)  or human cutaneous 
mast cells in vitro (12); and, in synergy with phorbol esters, 
the proliferation of human melanocytes in vitro (13). 
In this study, we investigated whether r-hSCF can influ- 
ence human mast cell or melanocyte development or func- 
tion in vivo. Portions of this work have been reported in 
abstract form (14, 15). 
Materials and Methods 
Patients and rohSCF Dosing Protocol.  10 women with stage IIIB 
or IV breast carcinoma who had volunteered to participate in an 
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up  to  five cycles of chemotherapy with  cyclophosphamide and 
doxorubicin were enrolled after providing informed consent and 
meeting the  following major  eligibility requirements:  no  prior 
chemotherapy for metastatic disease,  no  adjuvant chemotherapy 
within the preceeding 6 mo,  <250  mg/m  2 prior anthracyclines, 
age >18 yr, Karnofsky performance status  I>70%, absolute neu- 
trophil count  ~>2,000/mm  3, platelet count ~100,000/mm 3, he- 
moglobin  I>9  g/dl,  adequate  organ  function,  and  no  active 
asthma or other significant immediate hypersensitivity disorders. 
The protocol, which was approved by the Institutional Review 
Board for Human  Studies of the Dana-Farber Cancer Institute, 
called for patients to receive an initial 14-d course ofr-hSCF (5, 
10, 25,  or 50  p,g/kg/d, with each patient receiving only one of 
these  doses)  via daily subcutaneous  injection in the upper arm, 
anterior thigh, or abdominal wall (cycle 0), followed by a 7-d pe- 
riod of observation before initiation of chemotherapy. 
Histology.  Written informed consent was obtained from each 
patient to procure 4-mm punch biopsies of skin after induction of 
local anaesthesia (0.5-1.0 ml of 1% or 2% lidocaine, injected in- 
tradermally at least 1 cm away from the site to be biopsied). To 
assess the systemic effects ofr-hSCF on dermal mast cells, biopsies 
(separated by at least 3 cm) were obtained from the skin over the 
posterior iliac crest (i.e., at a site not injected with r-hSCF) before 
(day -1  or 0)  and on the last day (day 14)  of the first  period of 
r-hSCF dosing. Half of each biopsy was  immediately placed in 
10%  neutral buffered  formalin  (NBF)  and  the  other  half into 
freshly prepared  Carnoy's fixative. All sections were  coded,  to 
conceal  each  specimen's  identity,  before  microscopic  analysis. 
Carnoy's fixed,  paraffin-embedded sections  (4  ~m  thick)  were 
stained for 10-15 min with 0.5% alcian blue (Rowley Biochemi- 
cal  Institutes,  Inc.,  Rowley,  MA)  in  0.7  M  HC1,  rinsed,  and 
counterstained  with  0.25%  safranin  (Kowley  Biochemicals)  in 
0.125  M  HCI  for 2  h  (5),  and  the  numbers  of mast  cells per 
square millimeter of dermis were quantified at 400  ￿  by use of 
the Bioquant Morphometric  System (R  &  M  Biometrics, Inc., 
Nashville,  TN)  (6).  Biopsies  of hyperpignlented lesions  were 
fixed in NBF, embedded in paraffin,  and stained with the Fon- 
tana-Masson technique  to identify melanin (16)  or with hema- 
toxylin and eosin (H and E) to quantify melanocytes as number of 
basal clear cells per square millimeter of skin (17). 
Electron Microscopy.  Skin biopsies (performed as above) of the 
wheal-like lesions that developed 90-120 rain after r-hSCF injec- 
tion, and control biopsies of identically prepared contralateral sites 
(not  injected with  r-hSCF),  were  immediately immersed  in  a 
pool of freshly prepared fixative (2.0%  paraformaldehyde, 2.5% 
glutaraldehyde, and 0.025%  CaCl  2 in  0.1  M  sodium cacodylate 
buffer,  pH  7.4)  at room temperature,  trimmed,  and  then  fixed 
and processed for transmission electron microscopy (18). 
￿9  Quantification  of Mast Cell Mediators.  Serum specimens obtained 
before r-hSCF dosing (day -1) and on day 14, just before the last 
r-hSCF injection, and urine specimens obtained on day -1  and 
on day 14 or 15  (before or "~  d after the last r-hSCF injection), 
were  stored as 0.5-ml aliquots at  -20~  Because of histamine's 
short half-life in the circulation ("-q  rain), urinary levels of the 
major histamine metabolite, methyl-histamine, are used to assess 
systemic changes in histamine levels (19). Urine methyl-histamine 
was  measured  with  the  methyl-histamine  tLIA  kit,  exactly  as 
specified by the manufacturer  (Pharmacia Inc. Diagnostics, Co- 
lumbus, OH; detection range, 0.2-10.0 ~g/1). To account for in- 
dividual variation in urinary concentration, values were expressed 
as normalized methyl-histamine, i.e., micrograms of methyl-his- 
tamine per milligram of creatinine in the same aliquot of urine. In 
all patients, the serum blood urea nitrogen and creatinine levels 
were stable over the 2-wk period of r-hSCF dosing. 
Tryptase (stored in the cytoplasmic granules of most, if not all, 
human mast cells) is a more specific marker of mast cells than is 
histamine (20, 21). At least two tryptase genes occur in the human 
genome, encoding o~-tryptase and the r-'93% identical [3-tryptase 
(22). Serum tryptase was measured with the Tryptase RIACT kit 
(exactly as  specified by the  manufacturer  [Pharmacia  Diagnos- 
tics]); the capture antibody used in this assay (G5) recognizes pri- 
marily [3-tryptase,  which is not detectable (<1.0 ng/ml) in serum 
obtained from healthy control subjects (20).  Most samples were 
also  analyzed by using the new B12  capture assay that measures 
both oL- and 13-tryptase and can detect oe-tryptase  in blood from 
normal individuals (mean levels of~5  ng/ml, all values <20 ng/ 
ml) (20, 21). 
Statistics.  Serial observations for each individual were  com- 
pared by use of the 1-tailed paired Student's t test (after first estab- 
lishing that the differences between the baseline and post-r-hSCF 
dosing values conformed to a normal distribution). Data are ex- 
pressed as mean _+ SD. 
Results  and Discussion 
r-hSCF Induces  Dermal Mast  Cell Degranulation.  All  10 
patients developed a  raised, pruritic wheal with surround- 
ing erythema at r-hSCF injection sites (Fig. 1). The lesions 
were  clinically most prominent '--~90-120 rain after r-SCF 
injection, they were induced by every dose ofr-hSCF, and, 
at  any  given  dose  of r-hSCF,  the  intensity  of the  lesions 
that  developed  after  each  of the  injections  in  individual 
subjects did not appear to  change over the  14-d treatment 
period. Oral premedication with H1  (diphenhydramine 50 
mg,  orally,  each  6  h)  and  H 2  (ranitidine  150  rag,  orally, 
each  12 h)  antihistamines minimized the pruritis associated 
with these reactions but appeared to have little or no effect 
on the wheal and flare component of the responses. 
Biopsies of the wheals at r-hSCF injection sites, as well 
as  control biopsies of contralateral normal skin,  were  ob- 
tained  twice  from  two  individuals and  once  from  a  third 
subject, providing five r-hSCF injection sites and five con- 
trol sites for  electron microscopy. As illustrated in  Fig.  2, 
many  of the  dermal mast cells at all five r-hSCF injection 
sites exhibited extensive degranulation, including cytoplas- 
mic granule extrusion, a characteristic feature of anaphylac- 
tic-type  degranulation  in  human  skin  mast  cells  (18).  By 
Figure 1.  A wheal (area of central 
pallor)  with  surrounding  erythema 
(arrows) that developed ~90 rain af- 
ter  the  subcutaneous  injection  of 
r-hSCF (10 gtg/kg). 
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type degranulation of  a dermal mast cell in an r-hSCF injection site biopsy 
obtained 2 h after subcutaneous administration of the agent. Many struc- 
tures that represent fused cytoplasmic  granule membranes, some of them 
in continuity with the plasma membrane (arrowheads),  are present. There 
is also evidence of extrusion of cytoplasmic granule contents at the cell 
surface (arrows).  Bar, 1.0 Ixm. 
contrast, none of the mast cells in any of the control biop- 
sies  demonstrated  anaphylactic degranulation  (not shown). 
These  findings  are  the  first to  demonstrate  that  any cyto- 
kine can induce human mast cell degranulation in vivo. 
Three  subjects were withdrawn  from the  study because 
they exhibited distant adverse clinical effects that may have 
reflected  mast  cell  activation  in  response  to  injection  of 
r-hSCF,  including moderate  to severe  (grade  3  in severity 
according to the World Health Organization toxicity scale 
[22]) urticarial reactions and upper airway symptoms (cough, 
hoarseness,  or throat tightness).  A  complete description  of 
the results of the phase I trial ofr-hSCF, including both the 
hematological  findings  and  a  more  detailed  description  of 
the adverse events, will be reported separately (our unpub- 
lished data). 
r-hSCF Induces Dermal Mast Cell Hyperplasia.  The  mean 
total dermal mast cell density (number per square millime- 
ter) in the seven subjects who completed the first course of 
r-hSCF  treatment  increased by 67%  (75  +  31  [range 49- 
120] at day 14 vs. 45  +  22  [range 28-85]  at baseline,  P  = 
0.011),  with  significant  increases  in  the  mean  density  of 
mast cells in both the papillary dermis (254 -+ 87 on day 14 
vs.  173  -  89  at baseline,  P  <0.001)  and  reticular  dermis 
(51  -+  19  at  day  14 vs.  34  +  16  at baseline,  P  ~-  0.043). 
This is the first demonstration that any cytokine can induce 
human  mast  cell  hyperplasia  in  vivo.  Moreover,  human 
subjects appear to be more sensitive to the systemic effects 
ofr-hSCF on dermal mast cell development than are cyno- 
molgus monkeys (Macaca  fascicularis), in which  administra- 
tion  of r-hSCF  subcutaneously at  100  Ixg/kg/d for 21  d, 
did not result in significantly increased numbers  of dermal 
mast cells  in skin distant to sites  ofr-hSCF injection (6). 
r-hSCF  Treatment Results  in  Increased Systemic Levels of 
Mast Cell Mediators.  Each  of the  five  patients  for whom 
complete  data  are  available  (numbers  103,  125,  128,  138, 
and 162) exhibited an increase in normalized urine methyl- 
histamine over the course ofr-hSCF dosing. Mean (+  SD) 
values for micrograms of  methyl-histamine per milligram of 
creatinine increased "-~44%, from 0.126  (-  0.042)  at base- 
line to 0.182 (-  0.031) at day 14 or 15, P  =  0.006. 
The  G5  assay,  which  detects  primarily  13-tryptase,  de- 
tected  no  serum  tryptase  (<1.0  ng/ml)  at  baseline  or  on 
day 14 in all but one of the seven patients who completed 
14  d  of r-hSCF  dosing without  exhibiting  any symptoms 
suggestive  of  systemic  mast  cell  activation;  this  subject 
(number  128) had <1.0,  1.0, and 1.8 ng oftryptase/ml on 
days 0, 7, and  14,  respectively. By contrast,  the B12 assay, 
which detects both o~- and [3-tryptase, demonstrated a two- 
fold  or  greater  increase  in  tryptase  levels  after  14  d  of 
r-hSCF dosing in each of the five patients for whom com- 
plete data are available  (Table  1);  the magnitude of the in- 
crease in percentage  of serum tryptase between  day 0  and 
day  14  was  strongly  correlated  with  the  dose  of r-hSCF 
(R =  0.97,  P  ------- 0.006),  and  marked  increases  were  ob- 
served even in patients  who exhibited no systemic clinical 
adverse events during the  14-d dosing period.  In three pa- 
tients,  the  B12  assay also  documented  increases  in  serum 
tryptase  (of 68-166%)  in  specimens  obtained  4--20 h  after 
systemic  clinical  adverse  events  that  were  suggestive  of 
widespread  mast cell degranulation;  the  G5 assay detected 
Table  1.  Administration  of r-hSCF Results in Increased Levels of 
Serum Tryptase 
Study  Serum 
Patient  r-hSCF dose  day  tryptase 
~glkgld  nglml 
161  5  0  4 
14  10 
103  10  0  12 
14  29 
106  10  0  11 
*7  19 
57  32 
14  22 
"185  25  0  35 
[J5  93 
"123  50  0  2 
70  5 
128  50  0  19 
7  200 
14  251 
138  50  0  14 
14  140 
*Withdrawn from study after development of  a systemic reaction. 
*,SSpecimens obtained on day 7 before (:I:)  and 5 h after (w one 50 I~g/ 
kg dose of r-hSCF  that was associated with  a systemic reaction; this 
subject had  no subsequent systemic reactions to  10  I~g/kg doses of 
r-hSCF. 
II.￿82  obtained 20 h (IJ) or 4 h (~ after onset of systemic reac- 
tions. 
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neous hyperpigmentation (arrows) at 
3 sites (on the upper anterior thigh) 
that  had  been  injected  subcutane- 
ously with  r-hSCF (50  p~g/kg/site) 
more than 6 mo earlier. 
an increase in serum tryptase (to 2.6 ng/ml) in one ofthege 
three subjects (number  106).  These findings are consistent 
with  the  hypothesis that  [3-typtase is released primarily in 
association with extensive, systemic, anaphylactic-type mast 
cell degranulation  (21),  whereas  ot-tryptase appears in  the 
circulation as a  result of a  distinct pathway of nonanaphy- 
lactic release that reflects total body levels of mast cells (20). 
Notably,  the  increases in  serum tryptase levels detected 
over  the  14-d  course  of r-hSCF  dosing  (range  =  100  - 
1220%  increase)  greatly  exceeded  the  corresponding  in- 
creases  in  total  dermal mast  cell numbers  (range  =  4.5  - 
100%  increase)  in  the  same  five subjects;  in  four  of these 
patients, the day 14 serum tryptase values were in the range 
observed in naturally occurring systemic mastocytosis (i.e., 
>20  ng/ml)  (20).  M. fascicularis  that  had  been  dosed  for 
21  d  with 100  Ixg of r-hSCF/kg/d exhibited no significant 
increase in noninjection-site skin mast cells, but developed 
marked elevations of mast cell numbers  (4- to  128-fold in- 
creases) in organs with a relatively porous vasculature, such 
as  the  mesenteric  lymph  nodes,  bone  marrow,  liver,  and 
spleen (6).  Taken  together,  these findings suggest that  the 
quantification of the systemic effects of r-hSCF on dermal 
mast cell numbers in our patients may have underestimated 
the  effects of the  course  of r-hSCF  dosing  on  total body 
mast cell levels. 
SCF can maintain mast cell survival by suppressing apop- 
tosis (23-25).  Our protocol did not permit us to obtain ad- 
ditional biopsies of clinically normal  skin  in  our  patients, 
but  serum  tryptase  levels  in  other  subjects  dosed  with 
r-hSCF fell to approximately baseline levels within 2  wk of 
cessation of r-hSCF  dosing  (L.B.  Schwartz  et  al.,  unpub- 
lished  data).  This  finding  suggests  that  in  humans,  as  in 
mice  (25)  and  M. fascicularis  (6),  rSCF-induced  mast  cell 
hyperplasia is reversible upon cessation of cytokine dosing. 
rohSCF Promotes Epidermal  Hyperpigmentation  and Enhanced 
Melaninization as Well as Melanocyte Hyperplasia.  Five of the 
10 subjects treated with r-hSCF developed areas of striking 
cutaneous hyperpigmentation, 3-5  cm in diameter, at one 
or more r-hSCF injection sites (Fig. 3). These lesions were 
first noted during the initial 14 d  of r-hSCF administration 
before  chemotherapy  (cycle 0)  in  three  subjects  and  after 
chemotherapy, during cycle 3  or 4  of dosing, in two other 
subjects. In most instances, the lesions were first noted 3  or 
4  d  after r-hSCF injection at those  sites. When  hyperpig- 
Figure 4.  (A and B) H and E~stained sections of skin biopsies of (A), a site not injected with r-hSCF, obtained at the end (day 14) of the first course of 
r-hSCF administration, or of (B), an area of hyperpigmentation at a site  that had received a single injection of r-hSCF 2 mo earlier. There are increased 
numbers of melanocytes (arrowheads),  which appear as basal clear cells with separation from surrounding keratinocytes, in biopsy B compared with biopsy 
A. (C and D) Fontana-Masson~stained  sections, in which melanin is stained purple-black. (C) In a biopsy obtained before the start of r-hSCF injections, 
melanin is present focally in basal keratinocytes (arrow). (D) The same biopsy shown in A, demonstrating prominent melanin in virtually all basal kerati- 
nocytes (arrows)  and in occasional  keratinocytes (arrowheads)  above the basal  layer. (E) The same biopsy as in B, showing markedly increased melanization, 
with prominent melanin in all basal  keratinocytes and in many keratinocytes (arrowheads)  above the basal  layer. All biopsies are from the same patient. Bar 
in E, 25 p~m. 
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served at each r-hSCF injection site over the entire course 
of the study. The hyperpigmented skin lesions persisted for 
variable but generally long periods of time (2-12 mo), dur- 
ing which they gradually faded. 
In comparison with the skin biopsies obtained from the 
same subjects before the initiation ofr-hSCF administration 
(Fig.  4  C'), the hyperpigmented lesions exhibited markedly 
enhanced  epidermal melanization  (Fig.  4  E).  While  some 
of the  sites  also  exhibited  focal  perivascnlar infiltrates  of 
lymphocytes and eosinophils and occasional basophils, few 
melanophages were present,  indicating  that  the  enhanced 
melanization at these sites is unlikely to be of a postinflam- 
matory etiology  (26).  Moreover, modest increases in  epi- 
dermal melanization were also detected in some skin biop- 
sies obtained at the end (day 14) of the first cycle ofr-hSCF 
dosing at sites that had not been injected with r-hSCF and 
that clinically did not appear to be hyperpigmented (Fig.  4 
D). Taken together, these findings indicate that r-hSCF can 
promote the functional  activation of human melanocytes, 
as well as human mast cells. 
Biopsies of both pretreatment skin and sites of persistent 
(2-12-mo-old)  r-hSCF-induced  hyperpigmentation  were 
available  in  three  subjects  (numbers  161,  128,  and  138, 
treated with 5, 50, or 50 b~g ofr-hSCF/kg/d, respectively). 
The mean number of melanocytes in the hyperpigmented 
lesions was increased by >300% compared with that in the 
pretreatment  biopsies  (38  +  8  [range  29-44]  vs.  9  +_  2 
[range 7-11]  melanocytes per linear millimeter of epider- 
mis, respectively; P  --- 0.015)  (Figs.  4, A  and B).  None of 
the  melanocytes  appeared  dysplastic.  Moreover,  melano- 
cyte numbers were not increased in hyperpigmented areas 
that were biopsied within 2 wk of r-hSCF injection (n  = 
2), indicating that r-hSCF-induced hypermelanosis can oc- 
cur before the onset of melanocytic hyperplasia. Nor were 
melanocyte  numbers  significantly  increased  after  14  d  of 
r-hSCF  dosing in  skin biopsies from the iliac  crest,  a site 
distant from those directly injected with the cytokine (n = 
7)  (data not shown). This finding suggests that human me- 
lanocytes  may be  less  sensitive  to  the  systemic  effects of 
r-hSCF on proliferation than are human mast cells. 
It is not clear why some subjects injected with r-hSCF 
did not develop clinically detectable areas of hyperpigmen- 
tation  at the  injection  sites,  or whether this represented a 
qualitative or quantitative difference in the responses of the 
different patients. Notably, r-hSCF does not induce human 
melanocyte  proliferation  in  vitro  unless  a  second  agent 
(e.g., PMA)  is also present (13),  raising the possibility that 
individual  subjects may vary in the levels of other factors 
that contribute to the expression ofr-hSCF-induced effects 
on melanocyte development or function. 
Conclusions.  Our observations provide direct evidence 
that  r-hSCF  can  promote  the  hyperplasia  and  the  func- 
tional activation of two distinct SCFR. + populations in hu- 
mans in vivo, mast cells  and  melanocytes.  These findings 
thus  not  only  strengthen  the  evidence  that  endogenous 
SCF represents a critical regulator of the development and 
function of mast cells  and melanocytes in humans, as well 
as in experimental animals, but also support the view that 
the  increased production  or bioavailability of endogenous 
SCF may contribute to certain diseases associated with mast 
cell and/or melanocyte hyperplasia or hyperpigmentation. 
For  example,  our  observations  support  the  concept  that 
changes in levels of endogenous SCF may account for two 
of the  cardinal  features  of urticaria  pigmentosa  (27),  and 
may also contribute to mast cell hyperplasia and/or epider- 
mal hyperpigmentation in other settings. 
Our findings also  suggest that enhancing or suppressing 
local levels of SCF  (or other approaches for manipulating 
SCFR-dependent signaling) may be useful for increasing or 
reducing mast cell numbers or for promoting or reducing 
cutaneous  melanization,  in  settings  in which  these  effects 
are clinically desirable.  Finally, since blood levels of c~-tryptase 
are elevated in both naturally occurring  (20)  and r-hSCF- 
induced  iatrogenic  systemic  mastocytosis,  et-tryptase may 
prove to be a  practical and sensitive index for estimating 
total body mast cell numbers. 
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